Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S.
Upfront consideration for the transaction is $405 million, subject to working capital, closing costs, France reimbursement liability and other adjustments. An additional $45 million from Advanz is ...